No abstract

Transient receptor potential vanilloid 1 (TRPV1) antagonists are known to attenuate two typical symptoms of inflammatory hyperalgesia: thermal and mechanical. However, it is not clear whether the sites of participation of TRPV1 for each symptom are different. In this study, we clarified the difference between the site of TRPV1 involvement in both symptoms by analysing the anti-hyperalgesic activity of two kinds of TRPV1 antagonists given locally (i.e. intraplantarly and intrathecally) in rats with CFA (complete Freund's adjuvant)-induced inflammation. TRPV1 antagonists BCTC (N-(4-tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydropyrazine-1(2H)-carbox-amide, 1-300 microg) and SB-366791 (N-(3-methoxyphenyl)-4-chlorocinnamide, 30-300 microg) administered intraplantarly in a dose-dependent manner inhibited CFA-induced thermal hyperalgesia. In addition, CFA-induced thermal hyperalgesia was significantly reversed by intrathecal administration of 1-100 microg of BCTC and SB-366791. While intraplantar BCTC (1-300 microg) and SB-366791 (30-300 microg) did not reverse CFA-induced mechanical hyperalgesia, 1-100 microg of intrathecally administered BCTC and SB-366791 dose-dependently reduced mechanical hyperalgesia. Regression analysis showed that a correlation exists between the inhibitory effects on thermal hyperalgesia and mechanical hyperalgesia after intrathecal administration (correlation factor = 0.6521), but not after intraplantar administration (correlation factor = 0.0215). These data suggest that TRPV1 in the peripheral endings of the primary afferents plays a key role in thermal hyperalgesia, but it makes only a minor contribution in CFA-induced mechanical hyperalgesia. Furthermore, it is suggested that the spinal TRPV1 is critical in the development of both types of hyperalgesia.

Meltrin a/ADAM12 is a member of the ADAM/MDC family proteins characterized by the presence of metalloprotease and disintegrin domains. This protein also contains a single transmembrane domain and a relatively long cytoplasmic domain containing several proline-rich sequences. These sequences are compatible with the consensus sequences for binding the Src homology 3 (SH3) domains. To determine whether the proline-rich sequences interact with SH3 domains in several proteins, binding of recombinant SH3 domains to the meltrin a cytoplasmic domain was analysed by pulldown assays. The SH3 domains of Src and Yes bound strongly, but that of Abl or phosphatidylinositol 3-kinase p85 subunit did not. Full-length Grb2/Ash bound strongly, whereas its N-terminal SH3 domain alone did less strongly. Src and Grb2 in bovine brain extracts also bound to meltrin a cytoplasmic domain on anity resin. Furthermore, immunoprecipitation with a monoclonal antibody to meltrin a resulted in coprecipitation of Src and Grb2 with meltrin a in cell extracts, suggesting that Src and Grb2 are associated in vivo with meltrin a cytoplasmic domain. This notion was also supported by the ®ndings that exogenously expressed meltrin a cytoplasmic domain coexisted with Src and Grb2 on the membrane rues. The C-terminal Tyr901 of meltrin a was phosphorylated both in vitro and in cultured cells by v-Src. These results may imply that meltrin a cytoplasmic domain is involved in a signal transduction for some biological function through the interaction with SH3-containing proteins. Oncogene (2000) 19, 5842 ± 5850.

The involvement of spinal transient receptor potential vanilloid 1 (TRPV1) in formalin-evoked pain has remained unclear, because investigation of this kind of pain with selective antagonists has not been conducted. The purpose of this study is to investigate the participation of spinal TRPV1 in formalin-evoked pain with iodo-resiniferatoxin (I-RTX), a potent TRPV1-selective antagonist. I-RTX given intrathecally dose-dependently and significantly decreased the number of flinching responses in the formalin-evoked 1st and 2nd phase with ID50 values (drug dose producing 50% inhibition of response) of 1.0 and 3.8 microg, respectively, and concentration-dependently suppressed capsaicin-evoked calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) release from rat spinal cord slices with an IC50 value (drug concentration producing 50% inhibition of response) of 86 nM. Capsazepine, a classical non-selective TRPV1 antagonist, given intrathecally also inhibited formalin-evoked flinching in both the 1st and 2nd phase with ID50s of 420 and 200 microg, respectively, and CGRP-LI release from rat spinal cord slices with an IC50 of 7.8 microM. Ratios of in-vivo analgesic potencies of I-RTX and capsazepine well reflected their intrinsic in-vitro activity. These findings suggest that spinal TRPV1 participates in the transduction system of formalin-evoked pain.